Bioluminescent imaging and histopathological findings. (A) Bioluminescent imaging in five representative mice from each group (0, 10 and 20 mg/kg/day groups). Bioluminescent imaging showed that the extension of metastasis tended to be lower in the α-mangostin-treated groups compared to the control group. ( B) The implanted mammary carcinomas proved to be moderately differentiated adenocarcinoma. Scale bar = 50 μm. ( C) p53 immunohistochemistry of mammary carcinomas induced by BJMC3879luc2 cell inoculation. Note the nuclear staining for abnormal p53 protein, indicating that these cells carry mutant p53. Scale bar = 25 μm. ( D) Metastasis to a lymph node in a control mouse. Scale bar = 250 μm. Metastatic carcinoma cells filled the sinusoidal space (higher magnification in box, inset). ( E) A lymph node from a mouse given 20 mg/kg/day α-mangostin. Scale bar = 250 μm. Metastatic carcinoma cells filled the subcapsular sinus (higher magnification in box, inset). ( F) Metastatic foci in the lung of a control mouse. Many metastatic foci and small to large nodules were seen. Scale bar = 250 μm. ( G) Metastatic foci in the lungs of mice given 20 mg/kg/day α-mangostin. Scale bar = 250 μm. (A): Bioluminescent imaging ; (B and D-G): H&E stain; (C): p53 immunohistochemistry.